Fig. 4From: Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testingDistribution of expected variants vs. incidental pathogenic variants. Oncoprint shows the distribution of expected variants (red) vs. incidental pathogenic variants (blue) across 233 unique samples used for the validation of germline SNVs and IndelsBack to article page